Versant Capital Management’s Charles River Laboratories CRL Stock Holding History

Versant Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$445K	Sell	1,963 -132	-6%	-$23.5K	0.04%	330
2026 Q1	$361K	Buy	2,095 +308	+17%	+$57.1K	0.04%	367
2025 Q4	$356K	Sell	1,787 -21	-1%	-$3.81K	0.04%	312
2025 Q3	$283K	Sell	1,808 -47	-3%	-$7.46K	0.04%	370
2025 Q2	$281K	Sell	1,855 -481	-21%	-$64.1K	0.04%	348
2025 Q1	$352K	Buy	2,336 +2,172	+1,324%	+$364K	0.06%	244
2024 Q4	$30.3K	Buy	164 +150	+1,071%	+$28.9K	0.01%	800
2024 Q3	$2.76K	Sell	14 -43	-75%	-$8.94K	﹤0.01%	1480
2024 Q2	$11.8K	Hold	57	–	–	﹤0.01%	918
2024 Q1	$15.4K	Buy	57 +38	+200%	+$9.07K	﹤0.01%	593
2023 Q4	$4.49K	Sell	19 -13	-41%	-$2.56K	﹤0.01%	1003
2023 Q3	$6.27K	Hold	32	–	–	﹤0.01%	892
2023 Q2	$6.73K	Hold	32	–	–	﹤0.01%	919
2023 Q1	$6.46K	Buy	32 +18	+129%	+$4.08K	﹤0.01%	860
2022 Q4	$3.05K	Hold	14	–	–	﹤0.01%	1034
2022 Q3	$3K	Hold	14	–	–	﹤0.01%	964
2022 Q2	$3K	Hold	14	–	–	﹤0.01%	973
2022 Q1	$4K	Hold	14	–	–	﹤0.01%	936
2021 Q4	$5K	Hold	14	–	–	﹤0.01%	885
2021 Q3	$6K	Hold	14	–	–	﹤0.01%	830
2021 Q2	$5K	Hold	14	–	–	﹤0.01%	891
2021 Q1	$4K	Hold	14	–	–	﹤0.01%	1081
2020 Q4	$3K	Hold	14	–	–	﹤0.01%	1036
2020 Q3	$3K	Hold	14	–	–	﹤0.01%	967
2020 Q2	$2K	Hold	14	–	–	﹤0.01%	1042
2020 Q1	$1K	Sell	14 -13	-48%	-$1.95K	﹤0.01%	1120
2019 Q4	$4K	Sell	27 -32	-54%	-$4.43K	﹤0.01%	982
2019 Q3	$7K	Hold	59	–	–	﹤0.01%	833
2019 Q2	$8K	Sell	59 -7	-11%	-$949	﹤0.01%	807
2019 Q1	$9K	Hold	66	–	–	﹤0.01%	926
2018 Q4	$7K	Hold	66	–	–	﹤0.01%	913
2018 Q3	$8K	Hold	66	–	–	﹤0.01%	949
2018 Q2	$7K	Hold	66	–	–	﹤0.01%	985
2018 Q1	$7K	Sell	66 -7	-10%	-$755	﹤0.01%	975
2017 Q4	$7K	Hold	73	–	–	﹤0.01%	1015
2017 Q3	$7K	Sell	73 -5	-6%	-$514	﹤0.01%	952
2017 Q2	$7K	Hold	78	–	–	﹤0.01%	960
2017 Q1	$7K	Sell	78 -1	-1%	-$85	﹤0.01%	945
2016 Q4	$6K	Sell	79 -27	-25%	-$2.05K	﹤0.01%	968
2016 Q3	$8K	Sell	106 -4	-4%	-$335	﹤0.01%	871
2016 Q2	$9K	Hold	110	–	–	0.01%	807
2016 Q1	$8K	Hold	110	–	–	﹤0.01%	823
2015 Q4	$8K	Buy	+110	New	+$7.93K	0.01%	789

Other funds holding CRL

CIM

Confluence Investment Management St. Louis, Missouri $6.4B AUM 9.79% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

CPCPP

Canada Post Corporation Pension Plan Toronto, Canada $2.87B AUM 37.96% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12B AUM

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

MPPW

Mitchell & Pahl Private Wealth Oklahoma City, Oklahoma $272M AUM 29.72% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

Versant Capital Management's CRL Position: Q2 2026 in Review

Versant Capital Management reduced its Charles River Laboratories (CRL) stake by 6.3% in Q2 2026, selling an estimated $23.5K and leaving 1,963 shares worth $445K. The position accounts for 0.04% of the portfolio, ranked #330.

Versant Capital Management first reported a position in CRL in Q4 2015 and has held it in 43 quarters since. 71 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Versant Capital Management held 1,963 shares of Charles River Laboratories worth $445K as of Q2 2026.
Versant Capital Management sold 132 Charles River Laboratories shares in Q2 2026, an estimated $23.5K.
Charles River Laboratories made up 0.04% of Versant Capital Management's portfolio in Q2 2026, its #330 holding.
Versant Capital Management first reported a position in Charles River Laboratories in Q4 2015 and has held it in 43 quarters since.
71 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.